This month’s edition provides a focused review of newly approved and recently launched therapies. Expion Health monitors these developments closely to assess clinical relevance, therapeutic positioning, and potential implications for payers, providers, and patients.
Indication
UTEBZI (tebipenem pivoxil) is FDA approved to treat complicated urinary tract infections (cUTI), including pyelonephritis, in adults with limited or no alternative oral treatment options. It is the first and only oral carbapenem antibiotic to receive FDA approval.
Dosage and Administration
UTEBZI comes as a 300mg tablets. The standard dose for UTEBZI is 600mg (two 300mg tablets) taken by mouth every 6 hours for 7 to 10 days. UTEBZI can be taken with or without food. Full course of treatment should be completed.
Warnings and Precautions
Warnings include hypersensitivity reactions, seizures and central nervous system (CNS) effects, and carnitine depletion. Common side effects include diarrhea, headache, nausea, abdominal pain, increased liver enzymes, and Clostridioides difficile infection.
Mechanism of Action
UTEBZI exerts its antibacterial effect by binding to penicillin-binding proteins (PBPs) within bacterial cell walls, inhibiting cell wall synthesis and leading to bacterial cell death. The active ingredient in UTEBZI is tebipenem pivoxil, a prodrug that is absorbed and converted in the gastrointestinal tract to its active form, tebipenem.
Disease Background
Urinary tract infections (UTIs) are among the most frequent infections managed in outpatient settings. They occur disproportionately in females, with approximately 50%–60% of women experiencing at least one UTI during their lifetime. The prevalence of UTIs is particularly high among women aged 65 years and older, affecting nearly 20% of this population compared with about 11% of women overall. Although definitions of uncomplicated UTIs (uUTIs) and complicated UTIs (cUTIs) vary across clinical sources, uUTIs are typically diagnosed in healthy, noncatheterized individuals who have normal urinary tract anatomy and function, and no evidence of renal impairment. In contrast, cUTIs are generally associated with factors such as fever, urinary tract obstruction, nephrolithiasis, sepsis, indwelling urinary catheters, or involvement of the kidneys. UTIs occurring in males or immunocompromised individuals are also commonly classified as complicated infections.
Clinical Data
UTEBZI received FDA approval based on the Phase 3 PIVOT-PO clinical trial in 1,690 adult patients with cUTI or pyelonephritis. The trial met the primary endpoint of non-inferiority compared to intravenous imipenem-cilastatin for the primary outcome measure of overall response at the test-of-cure visit. The tebipenem group achieved a 58.5% overall success rate compared to a 60.2% overall success rate for the imipenem-cilastatin group. Clinical cure at the test of cure visit was 93.5% in the tebipenem group vs. 95.2% in the imipenem-cilastatin group. Microbiological response rates at test of cure visit were 60.3% in and 61.3% in the tebipenem and imipenem-cilastatin groups, respectively.
